Back to Search
Start Over
Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
- Source :
-
Future medicinal chemistry [Future Med Chem] 2019 Aug; Vol. 11 (16), pp. 2107-2130. Date of Electronic Publication: 2019 Aug 02. - Publication Year :
- 2019
-
Abstract
- Leishmaniasis is one of the major neglected tropical diseases in the world and it is considered endemic in 88 countries. This disease is transmitted by a Leishmania spp. infected sandfly and it may lead to cutaneous or systemic manifestations. The preconized treatment has low efficacy and there are cases of resistance to some drugs. Therefore, the search for new efficient molecular targets that can lead to the preparation of new drugs must be pursued. This review aims to evaluate both Leishmania enzymes PTR1 and DHFR-TS as potential drug targets, highlight their inhibitors and to discuss critically the use of chemoinformatics to elucidate interactions and propose new molecules against these enzymes.
- Subjects :
- Animals
Antiprotozoal Agents chemistry
Antiprotozoal Agents therapeutic use
Drug Discovery
Folic Acid Antagonists chemistry
Folic Acid Antagonists therapeutic use
Humans
Leishmania metabolism
Leishmaniasis drug therapy
Leishmaniasis parasitology
Molecular Targeted Therapy
Multienzyme Complexes metabolism
Oxidoreductases metabolism
Tetrahydrofolate Dehydrogenase metabolism
Thymidylate Synthase metabolism
Antiprotozoal Agents pharmacology
Folic Acid Antagonists pharmacology
Leishmania drug effects
Leishmania enzymology
Multienzyme Complexes antagonists & inhibitors
Oxidoreductases antagonists & inhibitors
Thymidylate Synthase antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1756-8927
- Volume :
- 11
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- Future medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 31370699
- Full Text :
- https://doi.org/10.4155/fmc-2018-0512